We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Manufacturers of new biologics could receive up to eight years of exclusivity in 12 countries under the Trans Pacific Partnership, a close reading of the deal shows. The specific terms of the contentious trade pact, which President Barack Obama inked with 11 other countries in October, were publicly released Nov. 6. Read More
The FDA has approved AstraZeneca’s metastatic non-small cell lung cancer drug Tagrisso in a first-of-its-kind indication targeting patients with the EGFR T790M mutation. Read More
It was a big day for Baxalta’s hemophilia franchise on Friday, with the company announcing that it had nabbed marketing authorization in the EU for Obizur, and the FDA giving its approval for Adynovate. Read More
A Merck subsidiary could lose patent protection on the popular antibiotic Cubicin next year, after a federal appellate court invalidated four of the company’s five patents on the drug. Read More
Horizon Pharma shareholders have approved the company’s issuance of more than 81.7 million new shares to help fund the Irish drugmaker’s hostile takeover of Depomed. Read More
Mylan’s attempted hostile takeover of Perrigo ended fast and ignominiously Nov. 13, with shareholders of the Irish OTC drugmaker largely spurning the generic giant’s bid for control. Read More